Judah Frommer
Stock Analyst at Morgan Stanley
(3.10)
# 1,150
Out of 4,854 analysts
185
Total ratings
58.96%
Success rate
5.4%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $102 → $129 | $127.97 | +0.80% | 2 | Jun 5, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $21.05 | +104.32% | 2 | May 9, 2025 | |
| ABVX ABIVAX Société Anonyme | Assumes: Equal-Weight | $12 | $8.28 | +44.93% | 1 | Mar 20, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $9.60 | +150.00% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $28.00 | -21.43% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $4.17 | +43.88% | 2 | Jan 13, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Equal-Weight | $31 | $19.43 | +59.55% | 1 | Nov 21, 2024 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $67.61 | +56.78% | 2 | Nov 6, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $11.48 | +204.88% | 1 | Oct 8, 2024 | |
| MURA Mural Oncology | Initiates: Overweight | $13 | $2.56 | +407.81% | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $0.91 | +230.11% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $5.92 | +575.68% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.14 | +1,045.37% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $36.58 | -17.99% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $11.22 | +104.99% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $52.05 | -3.94% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $42.77 | +229.67% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.42 | +815.75% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $2.41 | +273.44% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $20.15 | +9.18% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $6.05 | +15.70% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $7.24 | +10.50% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $13.69 | +236.01% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $1.21 | +478.51% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $17.14 | +220.89% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $73.32 | -37.26% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $88.04 | -44.34% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $1,011.00 | -63.40% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $77.64 | -60.07% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $74.41 | +2.14% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $113.25 | +60.71% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $94.28 | +13.49% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $118.38 | -19.75% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $21.42 | -15.95% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $125.86 | -7.83% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $111.39 | -65.89% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $168.70 | -86.96% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $65.93 | -46.91% | 9 | Apr 29, 2020 |
Blueprint Medicines
Jun 5, 2025
Maintains: Equal-Weight
Price Target: $102 → $129
Current: $127.97
Upside: +0.80%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $21.05
Upside: +104.32%
ABIVAX Société Anonyme
Mar 20, 2025
Assumes: Equal-Weight
Price Target: $12
Current: $8.28
Upside: +44.93%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $9.60
Upside: +150.00%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $28.00
Upside: -21.43%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $4.17
Upside: +43.88%
Apellis Pharmaceuticals
Nov 21, 2024
Initiates: Equal-Weight
Price Target: $31
Current: $19.43
Upside: +59.55%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $67.61
Upside: +56.78%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $11.48
Upside: +204.88%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $2.56
Upside: +407.81%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $0.91
Upside: +230.11%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $5.92
Upside: +575.68%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.14
Upside: +1,045.37%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $36.58
Upside: -17.99%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $11.22
Upside: +104.99%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $52.05
Upside: -3.94%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $42.77
Upside: +229.67%
May 16, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.42
Upside: +815.75%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $2.41
Upside: +273.44%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $20.15
Upside: +9.18%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $6.05
Upside: +15.70%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $7.24
Upside: +10.50%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $13.69
Upside: +236.01%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $1.21
Upside: +478.51%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $17.14
Upside: +220.89%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $73.32
Upside: -37.26%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $88.04
Upside: -44.34%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $1,011.00
Upside: -63.40%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $77.64
Upside: -60.07%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $74.41
Upside: +2.14%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $113.25
Upside: +60.71%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $94.28
Upside: +13.49%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $118.38
Upside: -19.75%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $21.42
Upside: -15.95%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $125.86
Upside: -7.83%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $111.39
Upside: -65.89%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $168.70
Upside: -86.96%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $65.93
Upside: -46.91%